Evidence map›Paper›PMID 39085563›Full record

ReviewMolecular biotechnology2025

Prospects of Innovative Therapeutics in Combating the COVID-19 Pandemic.

Thamby Rajah Mahendran, Binsin Cynthia, Ramesh Thevendran, Solayappan Maheswaran

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Characterization ofFrontiers in pharmacology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Thamby Rajah MahendranSchool of Biological Sciences, Universiti Sains Malaysia, 11800, Minden, Penang, Malaysia.ORCID http://orcid.org/0000-0002-9357-1704
Binsin CynthiaSchool of Biological Sciences, Universiti Sains Malaysia, 11800, Minden, Penang, Malaysia.ORCID http://orcid.org/0000-0002-5745-8982
Ramesh ThevendranCentre of Excellence for Nanobiotechnology & Nanomedicine (CoExNano), Faculty of Applied Sciences, AIMST University, 08100, Bedong, Kedah, Malaysia.
Solayappan MaheswaranCentre of Excellence for Nanobiotechnology & Nanomedicine (CoExNano), Faculty of Applied Sciences, AIMST University, 08100, Bedong, Kedah, Malaysia. maheswaran_s@aimst.edu.my.ORCID http://orcid.org/0000-0002-2629-4583

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The sudden global crisis of COVID-19, driven by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), demands swift containment measures due to its rapid spread and numerous problematic mutations, which complicate the establishment of herd immunity. With escalating fatalities across various nations no foreseeable end in sight, there is a pressing need to create swiftly deployable, rapid, cost-effective detection, and treatment methods. While various steps are taken to mitigate the transmission and severity of the disease, vaccination is proven throughout mankind history as the best method to acquire immunity and circumvent the spread of infectious diseases. Nonetheless, relying solely on vaccination might not be adequate to match the relentless viral mutations observed in emerging variants of SARS-CoV-2, including alterations to their RBD domain, acquisition of escape mutations, and potential resistance to antibody binding. Beyond the immune system activation achieved through vaccination, it is crucial to develop new medications or treatment methods to either impede the infection or enhance existing treatment modalities. This review emphasizes innovative treatment strategies that aim to directly disrupt the virus's ability to replicate and spread, which could play a role in ending the SARS-CoV-2 pandemic.

Indexed as

Antiviral AgentsCOVID-19COVID-19 Drug TreatmentSARS-CoV-2COVID-19 VaccinesHumansPandemicsSpike Glycoprotein, CoronavirusAntiviral AgentsCOVID-19 VaccinesSpike Glycoprotein, CoronavirusInnovativeMutationSARS-CoV-2TherapeuticVaccine

Identifiers

PMID39085563

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.